Astragalus: Traditional Tonic, Modern Evidence Gap

← Back to articles

Astragalus membranaceus (Huang Qi) has been a staple of Traditional Chinese Medicine for over two thousand years, used in formulas for fatigue, frequent infections, and recovery from illness. The modern supplement market for astragalus is much larger than the Western clinical-trial evidence supporting it — and where good-quality trials do exist, they tend to test astragalus as an adjunct inside conventional treatment, not as the stand-alone "immune-boosting longevity herb" sold online. The gap between what the bottle implies and what the data show is the whole story here, so it is worth walking through claim by claim.

The telomerase claim

Most of astragalus's modern anti-ageing marketing rests on cycloastragenol — a saponin derivative shown in cell culture to activate telomerase in immune cells. The first commercial product, TA-65, was studied in a one-year open-label program in cytomegalovirus-positive subjects and reported a decline in the percentage of senescent cytotoxic (CD8+/CD28−) T cells and a reduction in the fraction of critically short telomeres, but no increase in mean telomere length. According to PubMed, that study (Harley and colleagues, Rejuvenation Research) was small, industry-supported, and non-randomised, and the authors themselves wrote that controlled randomised trials were still needed (DOI 10.1089/rej.2010.1085). More than a decade on, those confirmatory trials have not produced robust, independent evidence that the cell-senescence shifts translate into longer life, fewer illnesses, or any patient-relevant outcome. Activating an enzyme in a dish is a mechanism, not a benefit, and "telomerase activator" is doing a great deal of rhetorical work on supplement labels that the human data do not support.

Cancer supportive care

The most-cited body of Western-readable evidence is in oncology supportive care. A 2006 meta-analysis in the Journal of Clinical Oncology pooled 34 randomised trials of astragalus-based Chinese herbal combinations added to platinum-based chemotherapy in advanced non-small-cell lung cancer (2,815 patients). Combination therapy was associated with a reduced risk of death at 12 months (risk ratio 0.67; 95% CI 0.52–0.87) and improved tumour response (RR 1.34), but the authors were explicit that study quality was low to moderate, blinding was rare, and the results required confirmation in rigorously controlled trials (DOI 10.1200/JCO.2005.03.6392). Nearly two decades later, that confirmation has not arrived in a form that has changed practice, and major oncology guidelines do not incorporate astragalus into standard care. A separate 2025 meta-analysis of eight trials reported that astragalus reduced cancer-related fatigue and improved quality of life, but again rated the evidence as small and low-quality, with insufficient grounds for a strong clinical recommendation (DOI 10.1177/15347354241313344). The recurring theme across this literature is a favourable point estimate sitting on top of weak methodology — promising enough to keep studying, not solid enough to act on alone.

Kidney disease: the best-studied use

If astragalus has a genuinely interesting clinical signal, it is in nephrology. A 2014 Cochrane review of 22 randomised trials (1,323 participants) found that astragalus added to conventional therapy for chronic kidney disease was associated with reduced proteinuria and higher haemoglobin and serum albumin — but the reviewers stressed that the patient-important endpoints they cared about most (time to dialysis, all-cause mortality) were not reported in any included study, and that "suboptimal methodological quality and poor reporting" prevented firm conclusions (DOI 10.1002/14651858.CD008369.pub2). A larger 2019 meta-analysis of 66 trials in diabetic kidney disease reached the same shape of conclusion: short-term reductions in albuminuria, proteinuria, and serum creatinine, undercut by low study quality, high heterogeneity, and likely publication bias — much of it from Chinese-language trials of injectable rather than oral astragalus (DOI 10.1016/j.jep.2019.111921). For someone with kidney disease, the right move is not a self-prescribed capsule but a conversation with a nephrologist, because the studied product, route, and dose rarely match what is on a retail shelf.

Immune modulation

Laboratory studies consistently show immunomodulatory effects — enhanced macrophage and natural-killer-cell activity, shifts in cytokine signalling. That bidirectional, "tune the immune system" pharmacology is the mechanistic basis for the traditional use in both immune weakness and recovery. But two cautions follow. First, immune effects in cell and animal models have not been shown to translate into fewer or shorter colds in well-designed human trials; the popular "boosts immunity" claim is largely an extrapolation. Second, the same bidirectional activity creates real uncertainty in the wrong settings. Astragalus should be avoided in organ-transplant recipients on immunosuppressants — where stimulating immunity risks rejection — and used only with practitioner oversight in active autoimmune disease.

Safety and quality

Astragalus root is generally well tolerated in trials, with adverse-event rates broadly similar to control across the kidney-disease meta-analyses above. The bigger practical problem is product chaos: bulk-herb powders, standardised root extracts, and cycloastragenol-enriched anti-ageing products differ by orders of magnitude in active-compound content, so the same labelled "1,000 mg astragalus" can deliver wildly different pharmacology. Cycloastragenol products in particular warrant third-party testing for actual content. Some commercial extracts may affect drug-metabolising (CYP450) enzymes, which matters for anyone on narrow-therapeutic-window medications such as anticoagulants, anticonvulsants, or transplant drugs. And note a labelling trap: Astragalus is a huge genus, and a few unrelated species (for example, locoweed types) are toxic — another reason to buy A. membranaceus root from a vendor that verifies species identity.

Bottom line

Astragalus is a reasonable adjunct within a TCM framework under practitioner guidance, and it has a real — if low-quality — research signal as add-on therapy in kidney disease and cancer supportive care. As a stand-alone longevity or immune supplement bought on telomerase marketing, the human evidence does not match the claims. If you choose to use it, start with a standardised root extract at roughly 500–1,500 mg/day, buy from a brand that does species and content testing, avoid it entirely if you are on immunosuppressants or have active autoimmune disease, and track objective outcomes with your clinician rather than relying on a general sense of feeling "more energised."

Sources

1. McCulloch M, See C, Shu XJ, et al. "Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials." Journal of Clinical Oncology, 2006;24(3):419–430. PMID 16421421. DOI: 10.1200/JCO.2005.03.6392.
2. Zhang HW, Lin ZX, Xu C, Leung C, Chan LS. "Astragalus (a traditional Chinese medicine) for treating chronic kidney disease." Cochrane Database of Systematic Reviews, 2014;(10):CD008369. PMID 25335553. DOI: 10.1002/14651858.CD008369.pub2.
3. Zhang L, Shergis JL, Yang L, et al. "Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis." Journal of Ethnopharmacology, 2019;239:111921. PMID 31034954. DOI: 10.1016/j.jep.2019.111921.
4. Sheng X, Yang L, Huang B, et al. "Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies." Integrative Cancer Therapies, 2025;24:15347354241313344. PMID 40302232. DOI: 10.1177/15347354241313344.
5. Harley CB, Liu W, Blasco M, et al. "A natural product telomerase activator as part of a health maintenance program." Rejuvenation Research, 2011;14(1):45–56. PMID 20822369. DOI: 10.1089/rej.2010.1085.